In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 4, 1999, Pages 291-297

  Johnson, David M ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; IMIPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; BACTERIUM ISOLATE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONFERENCE PAPER; DRUG SENSITIVITY; ENTEROBACTER; ENZYME ACTIVITY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PHILIPPINES; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; SALMONELLA; SERRATIA; STAPHYLOCOCCUS AUREUS; TECHNIQUE;

BACTERIA; CEPHALOSPORINS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS;

EID: 0033369503     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00100-5     Document Type: Conference Paper

References (37)

1. Barie P., Vogel S., Dellinger E., Rotstein O.D., Solomkin J.S., Yang J.Y., Baumgartner T.F. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg. 132:1997;1294-1302.
2. Barradell L.B., Bryson H.M. Cefepime A review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
3. Berne T.V., Yellin A.E., Appelbaum M.D. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet. 177:(suppl):1993;18-22.
4. Bolmstrom A, Arvidson S, Ericson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (Abst 1208). ICAAC, Los Angeles, CA.
5. Brown D.F.J., Brown L. Evaluation of the Etest A novel method of quantifying antimicrobial activity . J Antimicrob Chemother. 27:1991;185-190.
6. Burwen D.R., Banerjee S.N., Gaynes R.P. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis. 170:1994;1622-1625.
7. Bush K. Is it important to identify extended-spectrum β-lactamase-producing isolates? Eur J Clin Microbiol Infect Dis. 15:1996;361-364.
8. Jones R.N., Salazar J.C., Pfaller M.A., Doern G.V. Multi-center evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Colombia using the Etest method. Diagn Microbiol Infect Dis. 29:1997;265-272.
9. Frei R., Jones R.N., Pignatari A.C., Yamane N., Marco F., Hoban D.J. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime. Diagn Microbiol Infect Dis. 18:1994;167-173.
10. Fung-Tomc J.C., Gradelski E., Huczko E., Doughterty T.J., Kessler R.E., Bonner D.P. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother. 40:1996;1289-1293.
11. Gouin F., Papazian L., Martin C., Albanese J., Durbec O., Domart Y., Veyssier P., Leroy J., Gres J.J., Rollin C. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother. 23:(suppl B):1993;205-214.
12. Hancock R.E.W., Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 29:(suppl A):1992;1-6.
13. Hoepelman A.I.M., Kieft H., Aoun M. International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 32:(suppl B):1993;175-186.
14. Jacoby G.A., Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 34:1996;908-911.
15. Jaurequi L., Matzke D., Scott M., Minns P., Hageage G. Cefepime as treatment for osteomyelitis and other bacterial infections. J Antimicrob Chemother. 32:(suppl B):1993;141-149.
16. Jones R.N., Marshall S.A. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis. 19:1994;33-38.
17. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs A 1997 surveillance trial in 102 medical centers in the United States . Clin Infect Dis. 30:1997;215-228.
18. Kessler R.E., Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 100:(suppl 6A):1996;13S-19S.
19. Knothe H., Shah P., Krcmery V., Anatal M., Mitsuhaski S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 11:1983;315-317.
20. McCabe R., Chirurgi V., Farkos S.A., Haddow A., Heinz G., Greene S. A new therapeutic option for the treatment of pneumonia. Am J Med. 100:(suppl 6A):1996;60S-67S.
21. Monnet D.L., Biddle J.W., Edwards J.R., Culver D.H., Tolson J.S., Martone W.J., Tenover F.C., Gaynes R.P. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the United States, 1986-1993. Infect Cont Hosp Epidemiol. 18:1997;492-498.
22. National Committee for Clinical Laboratory Standards (1997) Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. Wayne, PA: NCCLS.
23. National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing; Ninth informational supplement M100-S9. Wayne, PA: NCCLS.
24. Neu H.C. Safety of cefepime A new extended-spectrum parenteral cephalosporin . Am J Med. 100:(suppl 6A):1996;68S-75S.
25. Philippon A., Arlet G., Lagrange P.H. Origin and impact of plasmid-mediated extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis. 13:1994;17-29.
26. Doern G.V., Jones R.N., Pfaller M.A., Erwin M., Ramirez-Rhonda C. Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. Diagn Microbiol Infect Dis. 30:1998;113-119.
27. Sader H.S., Mimica I., Rossi F., Zoccoli C., Montelli A.C., Sampaio J.L.M., Segura A.J.A., Magalhaes M., Nowakonski A., Mendes C.M.F. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagn Microbiol Infect Dis. 28:1997;87-92.
28. Sader H.S., Pfaller M.A., Jones R.N. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum β-lactamase-producing. Enterobacteriaceae Diagn Microbiol Infect Dis. 20:1994;203-208.
29. Saez-Llorens X., Castano E., Garcia E., Baez C., Perez M., Tejeira F., McCracken G.H. Jr. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother. 39:1995;937-940.
30. Sanders W.E., Tenney J.H., Kessler R.E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 23:1996;454-461.
31. Schrank J.H. Jr, Kelley J.W., McAllister C.K. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with Gram-negative bacteremia. Clin Infect Dis. 20:1995;56-58.
32. Schwartz R., Das Young L.R., Ramirez-Ronda C., Frank E. Current and future management of serious skin and skin-structure infections. Am J Med. 100:(suppl 6A):1996;90S-95S.
33. IMP) in Gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol. 34:1996;2909-2913.
34. Thauvin-Eliopoulos C., Tripodi M.F., Moellering R.C. Jr, Eliopoulos G.M. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 41:1997;1053-1057.
35. Pfaller M.A., Korten V., Jones R.N., Doern G.V. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactams in Turkey using the Etest method. Diagn Microbiol Infect Dis. 35:1999;65-73.
36. Pfaller M.A., Jones R.N., Doern G.V. Multi-center evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela using the Etest method. Diagn Microbiol Infect Dis. 30:1998;45-52.
37. Yellin A.E., Berne T.V., Appleman M.D., Heseltine P.N., Gill M.A., Okamoto M.P., Baker F.J., Holcomb C. A randomized study of cefepime versus gentamicin plus mezlocillin as an adjunct to surgery in patients with acute cholecystitis. Surg Gynecol Obstet. 177:(suppl):1993;23-29.